These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

670 related articles for article (PubMed ID: 29992802)

  • 1. What Commissioner Gottlieb's FDA Is Doing to Lower Prescription Drug Prices and Steps Congress Can Take to Help.
    Waxman H; Corr B; Martin K; Duong S
    Issue Brief (Commonw Fund); 2018 Apr; 2018():1-10. PubMed ID: 29992802
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Generic Drugs in the United States: Policies to Address Pricing and Competition.
    Gupta R; Shah ND; Ross JS
    Clin Pharmacol Ther; 2019 Feb; 105(2):329-337. PubMed ID: 30471089
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The High Cost of Prescription Drugs in the United States: Origins and Prospects for Reform.
    Kesselheim AS; Avorn J; Sarpatwari A
    JAMA; 2016 Aug 23-30; 316(8):858-71. PubMed ID: 27552619
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FDA's proposed regulations to expand access to investigational drugs for treatment use: the status quo in the guise of reform.
    Rossen BR
    Food Drug Law J; 2009; 64(1):183-223. PubMed ID: 19998746
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Getting to the Root of High Prescription Drug Prices.
    Waxman H; Corr B; Martin K; Duong S
    Issue Brief (Commonw Fund); 2017 Jul; 2017():1-10. PubMed ID: 28700190
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Scott Gottlieb Believes a Nimbler, Speedier FDA Can Spur Competition, Lower Prices.
    Burns J
    Manag Care; 2017 Aug; 26(8):16-18. PubMed ID: 28895814
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Export of pharmaceuticals and medical devices under the federal Food, Drug & Cosmetic Act: FDA's striking change in interpretation post-Shelhigh.
    Basile EM; Tolomeo D; Gluck E
    Food Drug Law J; 2009; 64(1):149-69. PubMed ID: 19998744
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FDA's Gottlieb Aims To End Biosimilars Groundhog Day.
    Kirkner RM
    Manag Care; 2019 Jan; 28(1):5-6. PubMed ID: 30883313
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Steady Increase In Prices For Oral Anticancer Drugs After Market Launch Suggests A Lack Of Competitive Pressure.
    Bennette CS; Richards C; Sullivan SD; Ramsey SD
    Health Aff (Millwood); 2016 May; 35(5):805-12. PubMed ID: 27140986
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association Between Market Competition and Prices of Generic Topical Dermatology Drugs.
    Li DG; Joyce C; Mostaghimi A
    JAMA Dermatol; 2018 Dec; 154(12):1441-1446. PubMed ID: 30383117
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmaceutical policy in the Netherlands: from price regulation towards managed competition.
    Boonen LH; van der Geest SA; Schut FT; Varkevisser M
    Adv Health Econ Health Serv Res; 2010; 22():53-76. PubMed ID: 20575228
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Do pharmaceutical prices rise anticipating branded competition?
    Ellyson AM; Basu A
    Health Econ; 2021 May; 30(5):1070-1081. PubMed ID: 33684255
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Special FDA designations for drug development: orphan, fast track, accelerated approval, priority review, and breakthrough therapy.
    Michaeli DT; Michaeli T; Albers S; Boch T; Michaeli JC
    Eur J Health Econ; 2024 Aug; 25(6):979-997. PubMed ID: 37962724
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FDA reform in Congress: FDA's concerns. Food and Drug Administration.
    James JS
    AIDS Treat News; 1996 Apr; (no 245):5-7. PubMed ID: 11363624
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmaceuticals and Medical Devices: FDA Oversight.
    White RS;
    Issue Brief Health Policy Track Serv; 2016 Dec; 2016():1-74. PubMed ID: 28252887
    [No Abstract]   [Full Text] [Related]  

  • 16. Pharmaceutical pricing: an empirical study of market competition in Chinese hospitals.
    Wu J; Xu J; Liu G; Wu J
    Pharmacoeconomics; 2014 Mar; 32(3):293-303. PubMed ID: 24190661
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reductions in Use of Colchicine after FDA Enforcement of Market Exclusivity in a Commercially Insured Population.
    Kesselheim AS; Franklin JM; Kim SC; Seeger JD; Solomon DH
    J Gen Intern Med; 2015 Nov; 30(11):1633-8. PubMed ID: 25855479
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Evolution of Supply and Demand in Markets for Generic Drugs.
    Frank RG; McGuire TG; Nason I
    Milbank Q; 2021 Sep; 99(3):828-852. PubMed ID: 34075623
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FDA's expanding postmarket authority to monitor and publicize food and consumer health product risks: the need for procedural safeguards to reduce "transparency" policy harms in the post-9/11 regulatory environment.
    Roller ST; Pippins RR; Ngai JW
    Food Drug Law J; 2009; 64(3):577-98. PubMed ID: 19999646
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmaceutical Drugs of Uncertain Value, Lifecycle Regulation at the US Food and Drug Administration, and Institutional Incumbency.
    Herder M
    Milbank Q; 2019 Sep; 97(3):820-857. PubMed ID: 31407412
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.